827.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$843.47
Aprire:
$840.055
Volume 24 ore:
535.13K
Relative Volume:
0.65
Capitalizzazione di mercato:
$85.22B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
20.17
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+4.22%
1M Prestazione:
+8.82%
6M Prestazione:
+5.11%
1 anno Prestazione:
+45.93%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
Regeneron stock slips on a $85.2 billion market value - AD HOC NEWS
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Robbins LLP Urges REGN Investors to Contact the Firm Before - GlobeNewswire
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Biotech Stocks To Watch TodaySeptember 4th - MarketBeat
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data - biocentury.com
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock steadies after strong Q2 figures and pipeline focus - AD HOC NEWS
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact SueWallSt - Morningstar
REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 - Morningstar
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals stock hits 52-week high at $847.60 - Investing.com
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? - Barchart.com
Why Did Regeneron Pharmaceuticals (REGN) Climb After Its Latest Update? - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
Regeneron stock gains after steady 2026 growth and legal action reminder - AD HOC NEWS
Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
REGN 2-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron stock draws investor interest as class action lawsuit and strong earnings frame the outloo - AD HOC NEWS
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) - The National Law Review
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP - Yahoo Finance
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline - Eastern Progress
Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial - marketscreener.com
REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials - Yahoo Finance
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - PR Newswire
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron: Why I Still See Upside After The Rally (NASDAQ:REGN) - Seeking Alpha
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Exploring Growth Potential with a Robust Pipeline and Strategic Alliances - DirectorsTalk Interviews
Levi & Korsinsky Reminds Regeneron Pharmaceuticals - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fenimore Christopher R. | EVP Finance CFO |
Aug 18 '26 |
Option Exercise |
381.92 |
6,283 |
2,399,603 |
24,583 |
| Guarini Kathryn | Director |
Aug 10 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Aug 10 '26 |
Sale |
800.00 |
400 |
320,000 |
603 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Option Exercise |
376.69 |
800 |
301,352 |
2,503 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Sale |
800.00 |
800 |
640,000 |
1,703 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):